ArticleTurkish journal of physical medicine and rehabilitation2025
Reliability and validity of the Turkish version of the Composite Autonomic Symptom Score in patients with fibromyalgia.
Article in Turkish journal of physical medicine and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Autonomic Symptoms and the Choroidal Vascularity Index in Fibromyalgia Patients.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to determine the Turkish validity and reliability of the Composite Autonomic Symptom Score (COMPASS-31) in patients with fibromyalgia. Patients and methods: The study included 117 patients (113 females, 4 males; mean age: 43.0±11.0 years; range, 20 to 61 years) diagnosed with fibromyalgia between November 2021 and February 2023. The COMPASS-31, Revised Fibromyalgia Impact Questionnaire (FIQR), and the 36-item Short-Form Health Survey (SF-36) were used to collect data. The reliability of the scale was tested with internal consistency and test-retest reliability, and the validity was determined with construct validity. For test-retest reliability, 31 individuals (27 females, 4 males; mean age: 42.0±10.0 years; range, 21 to 60 years) were reassessed after one week. To establish the construct validity of COMPASS-31, its correlation with FIQR and SF-36 was assessed. Results: Cronbach's alpha value was 0.912, and the intraclass correlation coefficient was 0.838, indicating high reliability and internal consistency. According to the construct validity analysis, COMPASS-31 showed a good positive correlation with FIQR (r=0.451, p<0.001), and good negative correlations were observed between COMPASS-31 and vitality, mental health, and general health subscales of SF-36 (r=-0.402, p>0.001; r=-0.404, p<0.001; r=-0.455, p<0.001). Conclusion: The Turkish version of the COMPASS-31 is valid and reliable to assess autonomic symptoms in patients with fibromyalgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.